Patents by Inventor Matthew A. Gonda

Matthew A. Gonda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110311445
    Abstract: Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth.
    Type: Application
    Filed: May 9, 2011
    Publication date: December 22, 2011
    Applicant: MORPHOTEK, INC.
    Inventors: Vernon L. Alvarez, Matthew A. Gonda
  • Publication number: 20100210546
    Abstract: This invention includes compositions and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof.
    Type: Application
    Filed: April 7, 2010
    Publication date: August 19, 2010
    Applicant: TRANSMOLECULAR, INC.
    Inventors: Vernon L. ALVAREZ, Matthew A. GONDA, Carol A. GRIMES
  • Publication number: 20100016446
    Abstract: Disclosed are stable, water-based topical creams comprising nitroglycerin and suitable for pharmaceutical and/or cosmetic use. Also disclosed are methods for preparing the creams. Also disclosed are methods for treating circulatory disorders, methods for preventing or alleviating insufficient circulation, methods for enhancing localized activity of systemically administered drugs, methods for enhancing circulation, and methods for promoting wound healing by administering the disclosed creams. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: July 21, 2009
    Publication date: January 21, 2010
    Inventors: Sylvia Gonda, Matthew A. Gonda
  • Publication number: 20080153746
    Abstract: Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth.
    Type: Application
    Filed: April 6, 2005
    Publication date: June 26, 2008
    Applicant: TRANSMOLECULAR, INC.
    Inventors: Vernon L. Alvarez, Matthew A. Gonda
  • Patent number: 6793926
    Abstract: This invention relates to novel nonmammalian carrier vectors and viruses useful in the production of high titers of recombinant viruses which may contain foreign DNA inserts or which may be point-mutated or deleted viruses, and methods of producing those viruses. The nonmammalian carrier vector (“carrier vector”) is a chimeric vector which includes those portions of a nonmammalian virus backbone which allow replication in a nonmammalian host cell. The carrier vector includes various nucleic acid cassettes, which may include an embedded recombinant viral genome containing a desired transgene, components necessary for production of a replication-defective recombinant virus containing the transgene, and domains that permit the carrier vector to bind to mammalian cells. The invention also provides methods of producing high concentrations of recombinant virus as a substantially homogeneous preparation, compositions to produce the recombinant virus, and novel recombinant viruses.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: September 21, 2004
    Assignee: Genovo, Inc.
    Inventors: Siyamak Rasty, Matthew A. Gonda, Haifeng Chen
  • Patent number: 6099847
    Abstract: The present invention provides, inter alia, recombinant chimeric nucleic acids encoding a Gag-fs-fusion partner fusion protein; a pseudovirion comprising a retroviral Gag protein and a fusion partner, wherein the fusion partner is present in a Gag-fs-fusion partner fusion protein; an immunogenic composition comprising a pseudovirion; a Gag-fs-fusion partner fusion protein; and a method of making the pseudovirions of the present invention.
    Type: Grant
    Filed: May 15, 1997
    Date of Patent: August 8, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Gregory J. Tobin, Matthew A. Gonda
  • Patent number: 5610060
    Abstract: An isolated bacterium of the genus Helicobacter, characterized by the 16S ribosomal RNA encoding nucleotide sequence defined in the Sequence Listing as SEQ ID NO:1 is provided. An isolated nucleic acid having the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:1 is provided. Such a nucleic acid can be used for diagnosis of infection with H. hepaticus. A nucleic acid of the present invention in a vector suitable for expression of the nucleic acid is also provided. The vector can be in a host suitable for expressing the nucleic acid. A purified antigen specific for H. hepaticus is provided. A method of making an animal model for chronic Helicobacter infection is also provided.
    Type: Grant
    Filed: June 24, 1994
    Date of Patent: March 11, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jerrold M. Ward, James G. Fox, Michael J. Collins, Jr., Peter L. Gorelick, Raoul E. Benveniste, Joseph G. Tully, Matthew A. Gonda, Bruce J. Paster, Floyd E. Dewhirst, III
  • Patent number: 5380830
    Abstract: Biologically active proviral molecular clones of bovine immunodeficiency-like virus and cell lines infected with the same have been prepared. Various utilities of the clones are described.
    Type: Grant
    Filed: November 24, 1992
    Date of Patent: January 10, 1995
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventor: Matthew A. Gonda